

**Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2016**

Rs. in Crs.

	Particulars	Quarter Ended			Year Ended
		30.06.2016	31.03.2016	30.06.2015	31.03.2016
<b>1</b>	<b>(a) Net Sales / Income from Operations</b>				
	Domestic	314.97	287.45	302.57	1,236.48
	Exports	420.81	338.11	286.96	1,925.92
	Total	735.79	625.56	589.53	3,162.40
	Less : Excise Duty	8.77	8.61	7.91	36.07
	Net Sales / Income from Operations	727.02	616.95	581.62	3,126.33
	<b>(b) Other Operating Income</b>	1.02	1.02	0.93	3.59
	<b>Total Income from Operations</b>	<b>728.03</b>	<b>617.97</b>	<b>582.54</b>	<b>3,129.92</b>
<b>2</b>	<b>Expenses</b>				
	(a) Cost of Materials consumed	159.88	112.51	152.35	642.24
	(b) Purchase of stock-in-trade	58.75	32.39	65.84	223.13
	(c) Changes in Inventories in trade and work in progress	(27.70)	(20.98)	(4.98)	(95.94)
	(d) Employee benefits expense	116.34	98.42	85.86	420.86
	(e) Research and Development Expense	79.46	111.04	47.95	307.06
	(f) Depreciation & Amortization Expense	19.38	24.40	12.89	72.21
	(g) Other Expenses	184.35	141.95	131.21	625.88
	<b>Total Expenses</b>	<b>590.46</b>	<b>499.72</b>	<b>491.12</b>	<b>2,195.44</b>
<b>3</b>	<b>Profit from Operations before Other Income, finance costs &amp; exceptional items</b>	<b>137.58</b>	<b>118.24</b>	<b>91.43</b>	<b>934.48</b>
<b>4</b>	Other Income	0.39	2.62	0.03	5.51
<b>5</b>	<b>Profit from ordinary activities before finance costs &amp; exceptional items</b>	<b>137.97</b>	<b>120.87</b>	<b>91.46</b>	<b>939.99</b>
<b>6</b>	Finance Costs	1.07	1.30	0.62	3.68
<b>7</b>	<b>Profit from ordinary activities before tax</b>	<b>136.90</b>	<b>119.57</b>	<b>90.84</b>	<b>936.31</b>
<b>8</b>	<b>Tax Expense</b>				
	Provision for Current Tax	33.27	27.11	19.17	198.75
	Provision for Deferred Tax Liability	-	0.65	-	17.55
<b>9</b>	<b>Net Profit from ordinary activities after tax</b>	<b>103.63</b>	<b>91.81</b>	<b>71.67</b>	<b>720.01</b>
<b>10</b>	Share of Profit / (loss) of Associates & Joint Venture	0.11	(0.45)	0.06	(0.15)
<b>11</b>	<b>Net Profit after tax and share of profit / (loss) of associates</b>	<b>103.75</b>	<b>91.36</b>	<b>71.73</b>	<b>719.86</b>
<b>12</b>	<b>Other Comprehensive Income (after tax)</b>	<b>(1.72)</b>	<b>0.65</b>	<b>(1.56)</b>	<b>(0.23)</b>
<b>13</b>	<b>Total Comprehensive Income</b>	<b>102.02</b>	<b>92.01</b>	<b>70.17</b>	<b>719.63</b>
<b>14</b>	Paid up Equity Share Capital ( Face value of share Rs 2/- )	37.70	37.70	37.70	37.70
<b>15</b>	Reserves excluding Revaluation Reserve				1,562.84
<b>16</b>	Basic & Diluted EPS (Not Annualised)	5.41	4.88	3.72	38.17



**Notes :**

- 1 The above consolidated results, have been reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
- 2 The above consolidated results, have been prepared in accordance with IND AS notified under the Companies (Indian Accounting Standards) Rules, 2015.
- 3 Reconciliation of Net Profit between Previous GAAP and IND AS

Consolidated Financial Results	Rs. In Crs.
	Quarter
	Ended
Net Profit	30.06.2015
Net Profit under Previous GAAP	69.88
Actuarial gain / (loss) on employee defined benefit funds recognised in Other Comprehensive Income	1.56
Impact on account of measuring options at fair value through profit and loss.	0.29
Net Profit under IND AS	71.73

- 4 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
- 5 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara  
Date : 29th July, 2016



For Alembic Pharmaceuticals Limited

  
Chirag Amin  
Chairman and CEO

Visit us at [www.alembic-india.com](http://www.alembic-india.com)



**Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2016**

Rs. in Crs.

	Particulars	Quarter Ended			Year Ended
		30.06.2016	31.03.2016	30.06.2015	31.03.2016
<b>1</b>	<b>(a) Net Sales / Income from Operations</b>				
	Domestic	314.97	287.45	302.57	1,236.48
	Exports	381.42	299.91	278.49	1,768.99
	Total	696.39	587.36	581.05	3,005.47
	Less : Excise Duty	8.77	8.61	7.91	36.07
	Net Sales / Income from Operations	687.62	578.75	573.14	2,969.40
	<b>(b) Other Operating Income</b>	0.96	0.98	0.92	3.55
	<b>Total Income from Operations</b>	<b>688.58</b>	<b>579.72</b>	<b>574.07</b>	<b>2,972.95</b>
<b>2</b>	<b>Expenses</b>				
	(a) Cost of Materials consumed	162.86	112.51	152.35	642.24
	(b) Purchase of stock-in-trade	62.67	59.40	65.84	255.13
	(c) Changes in Inventories in trade and work in progress	(27.70)	(20.98)	(4.98)	(95.94)
	(d) Employee benefits expense	108.65	94.28	82.89	403.80
	(e) Research and Development Expense	63.10	73.04	40.23	216.15
	(f) Depreciation & Amortization Expense	19.07	24.11	12.89	71.86
	(g) Other Expenses	147.03	122.60	127.19	568.85
	<b>Total Expenses</b>	<b>535.68</b>	<b>464.95</b>	<b>476.40</b>	<b>2,062.09</b>
<b>3</b>	<b>Profit from Operations before Other Income, finance costs &amp; exceptional items</b>	<b>152.90</b>	<b>114.77</b>	<b>97.66</b>	<b>910.87</b>
<b>4</b>	Other Income	0.40	2.63	0.03	5.51
<b>5</b>	<b>Profit from ordinary activities before finance costs &amp; exceptional items</b>	<b>153.30</b>	<b>117.40</b>	<b>97.69</b>	<b>916.38</b>
<b>6</b>	Finance Costs	0.59	0.81	0.36	2.37
<b>7</b>	<b>Profit from ordinary activities before tax</b>	<b>152.71</b>	<b>116.59</b>	<b>97.33</b>	<b>914.01</b>
<b>8</b>	<b>Tax Expense</b>				
	Provision for Current Tax	32.97	26.94	19.17	198.11
	Provision for Deferred Tax Liability	-	0.45	-	17.35
<b>9</b>	<b>Net Profit from ordinary activities after tax</b>	<b>119.74</b>	<b>89.20</b>	<b>78.15</b>	<b>698.55</b>
<b>10</b>	<b>Other Comprehensive Income (after tax)</b>	<b>(1.72)</b>	<b>0.65</b>	<b>(1.56)</b>	<b>(0.23)</b>
<b>11</b>	<b>Total Comprehensive Income</b>	<b>118.02</b>	<b>89.85</b>	<b>76.59</b>	<b>698.32</b>
<b>12</b>	Paid up Equity Share Capital ( Face value of share Rs. 2/- )	37.70	37.70	37.70	37.70
<b>13</b>	Reserves excluding Revaluation Reserve				1,492.58
<b>14</b>	Basic & Diluted EPS (Not Annualised)	6.35	4.73	4.15	37.06



**Notes :**

- 1 The above standalone results, have been reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
- 2 The above standalone results, have been prepared in accordance with IND AS notified under the Companies (Indian Accounting Standards) Rules, 2015.
- 3 Reconciliation of Net Profit between Previous GAAP and IND AS

Standalone Financial Results	Rs. In Crs.
	Quarter
	Ended
Net Profit	30.06.2015
Net Profit under Previous GAAP	76.30
Actuarial gain / (loss) on employee defined benefit funds recognised in Other Comprehensive Income	1.56
Impact on account of measuring options at fair value through profit and loss.	0.29
Net Profit under IND AS	78.15

- 4 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
- 5 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.



For Alembic Pharmaceuticals Limited

  
Chirayu Amin  
Chairman and CEO

Place : Vadodara  
Date : 29th July, 2016

Visit us at [www.alembic-india.com](http://www.alembic-india.com)

